thrd - Search News

Fintel on MSN · 9h

Morgan Stanley Downgrades Third Harmonic Bio (THRD)

Fintel reports that on February 12, 2025, Morgan Stanley downgraded their outlook for Third Harmonic Bio (NasdaqGM:THRD) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 433.54% Upside As of January 29,

Business Insider · 1d

Raymond James downgrades Third Harmonic Bio on uncertainty for only asset

As previously reported, Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform and removed the firm’s prior $18

Hosted on MSN · 1d

Third Harmonic stock rating cut by Raymond James

James made a notable change in their assessment of Third Harmonic (NASDAQ:HLIT) Bio (NASDAQ:THRD), downgrading the biotechnology company's stock rating from Outperform to Market Perform. According to InvestingPro data,

TipRanks on MSN · 1d

Third Harmonic Bio downgraded to Market Perform from Outperform at Raymond James

Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform. Published first on TheFly – the ultimate source for

1d

Third Harmonic halting non-THB335 research, reducing workforce by 50%

In parallel with THB335 Phase 2 readiness activities, Third Harmonic Bio (THRD) is initiating a process to identify opportunities to maximize ...

Wall Street Journal26d

Third Harmonic Bio Inc.

1 Day THRD 1.94% DJIA 0.78% Russell 2K 0.40% Health Care/Life Sciences 1527.34% ...

Third Harmonic Bio, Inc. Common Stock (THRD) Institutional Holdings

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

1d

Third Harmonic Bio announces Phase 1 clinical results for THB335

Third Harmonic Bio (THRD) announced results from its Phase 1 single and multiple ascending dose clinical trial of THB335 in healthy volunteers.

1d

Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value ...

Third Harmonic Bio, Inc. Common Stock (THRD) Revenue EPS

© 2023 EDGAR®Online LLC, a subsidiary of OTC Markets Group. All rights reserved. EDGAR® and SEC® are trademarks of the U.S. Securities and Exchange Commission ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results